Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions
In Sweden, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2009 and replaced by the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) or the 13-valent PCV (PCV13) from late 2009. We assessed the impact of PCVs on rates of antibiotic prescribi...
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Taylor & Francis Group
2022-01-01
|
| Edice: | Human Vaccines & Immunotherapeutics |
| Témata: | |
| On-line přístup: | http://dx.doi.org/10.1080/21645515.2021.1942712 |